



Press release

Swiss Financial Market Supervisory Authority FINMA fully dismissed appeals of Kun Shen, Mengke Cai, Xu Xiang, Himalaya (Cayman Island) TMT Fund, and Himalaya Asset Management Ltd. against TOB decision – voting rights of said parties again suspended

Tel Aviv / Zurich, 26 November 2018 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that on 23 November 2018 the Swiss Financial Market Supervisory Authority FINMA resolved to reject the appeals of Kun Shen, Mengke Cai, Xu Xiang, Himalaya (Cayman Island) TMT Fund, and Himalaya Asset Management Ltd. against the decision of the Swiss Takeover Board (TOB) of 1 September 2018 (decision 672/04). As a consequence of the decision of FINMA, the voting rights of Kun Shen, Mengke Cai, Xu Xiang, Himalaya (Cayman Island) TMT Fund, and Himalaya Asset Management Ltd. are suspended until a mandatory tender offer is published, and no further deadline for the launch of a mandatory tender offer is granted to the appellants. The parties may appeal against this decision of FINMA within 10 calendar days.

For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit the web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.